GlassScriptPhysician profile
Christine Greer
NPI 1477940955
$9,822.86
in general payments reported to CMS, 2019-2025
29 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $1,046 · 2023: $3,422 · 2024: $1,933 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318 · Consulting Fee: $1,100 · Travel and Lodging: $676 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,317.78 |
| Consulting Fee | $1,100.00 |
| Travel and Lodging | $675.74 |
| Education | $190.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,573.79 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,723.69 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $990.70 | 2021-2025 | Clareon, Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol |
| Sun Pharmaceutical Industries INC. | $675.60 | 2022-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $511.35 | 2022-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $508.54 | 2024-2025 | Xdemvy |
| Allergan, INC. | $260.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $248.45 | 2021-2023 | |
| Amgen INC. | $244.38 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $226.78 | 2023-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $213.74 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $212.52 | 2023-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Horizon Therapeutics Plc | $184.11 | 2021-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $178.58 | 2025 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $174.93 | 2023-2025 | Tecnis Simplicity, Tecnis Iol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $154.64 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $154.42 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $147.60 | 2024 | Oxervate |
| Argenx US, INC. | $121.83 | 2025 | |
| Rxsight INC | $66.72 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $59.29 | 2024 | Omni Surgical System |
| Astellas Pharma US INC | $45.55 | 2023-2024 | Izervay |
| Glaukos Corporation | $29.53 | 2025 | Idosetr |
| New World Medical,INC. | $28.46 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Eyepoint US, INC. | $23.72 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $20.25 | 2025 | |
| Aerie Pharmaceuticals, INC. | $16.05 | 2021 | |
| Ucb, INC. | $14.82 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.